Adapted from the presentation ‘COPD – Where are we now?’, which took place at the Frontiers in Respiratory Medicine meeting, October 21st, 2011. MIMS Ireland Copyright®
Update on COPD
January 1, 2012 By Leave a Comment
Prevalence Moderate and Severe COPD affects one in 10 people The prevalence of COPD is increasing in Ireland, and COPD is expected to be the third cause of death by 2020. BOLD, a worldwide study including close to 10,000 participants, aimed to measure the prevalence of COPD, its risk factors and their variation across countries [...]
New therapeutic targets in asthma
January 1, 2012 By Leave a Comment
Towards endotype-specific therapy Phenotypes vs Endotypes One way to classify asthma involves identifying the phenotypes of asthma – that is the clusters of properties observed in different types of asthma. Criteria related to clinical aspects (e.g. severity and frequency of exacerbations, airflow restriction, age of onset, treatment effect), type of inflammatory cells (eosinophils or neutrophils) [...]
Domperidone – Risk of Cardiac Disorders
January 1, 2012 By Leave a Comment
Products include Domerid/Motilium Domperidone is a propulsive agent and a dopamine antagonist with antiemetic properties. It is authorised for use in adults for the relief of nausea and vomiting, epigastric sense of fullness, upper abdominal discomfort and regurgitation of gastric contents, and in children for the relief of nausea and vomiting. The risk of QTc [...]
Anti-doping: 2012 Guide for Prescribers
January 1, 2012 By Leave a Comment
The World Anti-Doping Code, published by the World Anti-Doping Agency (WADA), harmonises anti-doping regulations across all sports and in all countries. This Code includes a list of substances and methods which are prohibited in sport. Some of these substances are contained in medicinal products marketed in Ireland. However, in recognition of the fact that some [...]
Dexdor
January 1, 2012 By Leave a Comment
Company: Orion Pharma (Ireland) Ltd. Legal category: Prescription. Hospital. Sport permitted. Active ingredient: Dexmedetomidine 100µg/ml. Description: Concentrate for solution for infusion. Presentation: 4ml-4, €160; 10ml-4, €360. Indication: Sedation of intensive care unit patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3). [...]
Jext
January 1, 2012 By Leave a Comment
Company: ALK-Abello A/S. Legal category: Prescription. GMS. Sport prohibited. Active ingredient: Adrenaline (as tartrate) 150µg, 300µg. Description: Solution for injection in pre-filled pen. Presentation: 150µg-1, €32.79; 300µg-1, €32.79. Indications: Emergency treatment of severe acute allergic reactions to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis. Pharmacology: [...]
Rolyprexa DisTab
January 1, 2012 By Leave a Comment
Company: Rowex Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Olanzapine 5mg, 10mg, 15mg, 20mg. Description: Orodispersible, round, yellow tablets. 5mg, 15mg: Biconvex. 10mg, 20mg: Flat. Presentations: 5mg-28, €48.68; 10mg-28, €88.51; 15mg-28, €132.77; 20mg-28, €177.01. Indications: Treatment of schizophrenia. Treatment of moderate to severe manic episode. Prevention of recurrence of manic episodes in patients [...]
Valsartan Actavis
January 1, 2012 By Leave a Comment
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Valsartan 40mg, 80mg, 160mg. Description: Film-coated tablets. 40mg, 160mg: Yellow, oval, scored on one side and marked V on reverse, 9mm or 15mm diameter respectively. 80mg: Pink, round, scored on both sides, marked V on one side. All: Can be divided into equal [...]
Valsartan HCTZ
January 1, 2012 By Leave a Comment
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport prohibited. Active ingredients: Valsartan/HCTZ 80/12.5mg, 160/12.5mg, 160/25mg. Description: Pink, red or orange, oval, film-coated tablets marked V on one side and H on reverse, respectively. Presentation: 80/12.5mg-28, €16.16; 160/12.5mg-28, €21.11; 160/25mg-28, €21.83. Indication: Treatment of essential hypertension in adults whose blood pressure (BP) is not adequately [...]
Loading ...
